Loading…

Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience

Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients fr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical transplantation 2022-05, Vol.36 (5), p.e14591-n/a
Main Authors: Chen, Qiudong, Singer‐Englar, Tahli, Kobashigawa, Jon A., Roach, Amy, Emerson, Dominic, Megna, Dominick, Ramzy, Danny, Catarino, Pedro, Patel, Jignesh K., Kittleson, Michelle, Czer, Lawrence, Chikwe, Joanna, Esmailian, Fardad
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3
cites cdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3
container_end_page n/a
container_issue 5
container_start_page e14591
container_title Clinical transplantation
container_volume 36
creator Chen, Qiudong
Singer‐Englar, Tahli
Kobashigawa, Jon A.
Roach, Amy
Emerson, Dominic
Megna, Dominick
Ramzy, Danny
Catarino, Pedro
Patel, Jignesh K.
Kittleson, Michelle
Czer, Lawrence
Chikwe, Joanna
Esmailian, Fardad
description Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections. Results Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p > .5). Conclusions In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.
doi_str_mv 10.1111/ctr.14591
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11144456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2620081162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</originalsourceid><addsrcrecordid>eNp1kb9OHDEQxq0oKBwkRV4AuQzFgWe9f27TROgEAemkSBGpLa89Phx27YvtPaCjpOQZeZL4OIKSIm7s8fzmm9F8hHwEdgT5HKsUjqCsWnhDJsDbdsoYFG_JhLWsyO-a75K9GH_m3xrq6h3Z5RXjrGhmE_Kw8G75dP-YMAzUj0n5ASOVJsf0CmVINAXp4qqXLslkvaNjtG5J8Zau7dpT2fd-GTJPVxhMzmXCOhqTdFoGTYON11R750P8TE_oprbH3E-h27TA21xm0Sl8T3aM7CN-eLn3yY-z08v5-XTx7evF_GQxVWWefmpYpxtoK9PhTDI0JaA2qEBxANnpipfQNLxmlS6KTgKXpmw7jZqZmjWaKb5Pvmx1V2M3oN7MEWQvVsEOMtwJL634N-PslVj6tciLLsuyqrPCpxeF4H-NGJMYbFTY5xWhH6Mo6oKxGUBdZPRwi6rgYwxoXvsA2wiCyNaJZ-sye_D3YK_kH68ycLwFbmyPd_9XEvPL71vJ30nhqjA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2620081162</pqid></control><display><type>article</type><title>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</title><source>Wiley</source><creator>Chen, Qiudong ; Singer‐Englar, Tahli ; Kobashigawa, Jon A. ; Roach, Amy ; Emerson, Dominic ; Megna, Dominick ; Ramzy, Danny ; Catarino, Pedro ; Patel, Jignesh K. ; Kittleson, Michelle ; Czer, Lawrence ; Chikwe, Joanna ; Esmailian, Fardad</creator><creatorcontrib>Chen, Qiudong ; Singer‐Englar, Tahli ; Kobashigawa, Jon A. ; Roach, Amy ; Emerson, Dominic ; Megna, Dominick ; Ramzy, Danny ; Catarino, Pedro ; Patel, Jignesh K. ; Kittleson, Michelle ; Czer, Lawrence ; Chikwe, Joanna ; Esmailian, Fardad</creatorcontrib><description>Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections. Results Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p &gt; .5). Conclusions In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/ctr.14591</identifier><identifier>PMID: 35030278</identifier><language>eng</language><publisher>Denmark</publisher><subject>Allografts ; heart (allograft) function/dysfunction ; heart disease ; Heart Diseases ; Heart Transplantation - adverse effects ; Humans ; organ perfusion and preservation ; Organ Preservation ; patient survival ; Perfusion ; Tissue Donors</subject><ispartof>Clinical transplantation, 2022-05, Vol.36 (5), p.e14591-n/a</ispartof><rights>2022 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</citedby><cites>FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</cites><orcidid>0000-0002-2475-4312 ; 0000-0001-9308-3172 ; 0000-0003-4492-2691 ; 0000-0002-1445-6610 ; 0000-0001-5728-0152 ; 0000-0002-8169-0781 ; 0000-0002-6154-1199 ; 0000-0001-5744-2625 ; 0000-0002-7328-5903</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35030278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Qiudong</creatorcontrib><creatorcontrib>Singer‐Englar, Tahli</creatorcontrib><creatorcontrib>Kobashigawa, Jon A.</creatorcontrib><creatorcontrib>Roach, Amy</creatorcontrib><creatorcontrib>Emerson, Dominic</creatorcontrib><creatorcontrib>Megna, Dominick</creatorcontrib><creatorcontrib>Ramzy, Danny</creatorcontrib><creatorcontrib>Catarino, Pedro</creatorcontrib><creatorcontrib>Patel, Jignesh K.</creatorcontrib><creatorcontrib>Kittleson, Michelle</creatorcontrib><creatorcontrib>Czer, Lawrence</creatorcontrib><creatorcontrib>Chikwe, Joanna</creatorcontrib><creatorcontrib>Esmailian, Fardad</creatorcontrib><title>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections. Results Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p &gt; .5). Conclusions In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.</description><subject>Allografts</subject><subject>heart (allograft) function/dysfunction</subject><subject>heart disease</subject><subject>Heart Diseases</subject><subject>Heart Transplantation - adverse effects</subject><subject>Humans</subject><subject>organ perfusion and preservation</subject><subject>Organ Preservation</subject><subject>patient survival</subject><subject>Perfusion</subject><subject>Tissue Donors</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kb9OHDEQxq0oKBwkRV4AuQzFgWe9f27TROgEAemkSBGpLa89Phx27YvtPaCjpOQZeZL4OIKSIm7s8fzmm9F8hHwEdgT5HKsUjqCsWnhDJsDbdsoYFG_JhLWsyO-a75K9GH_m3xrq6h3Z5RXjrGhmE_Kw8G75dP-YMAzUj0n5ASOVJsf0CmVINAXp4qqXLslkvaNjtG5J8Zau7dpT2fd-GTJPVxhMzmXCOhqTdFoGTYON11R750P8TE_oprbH3E-h27TA21xm0Sl8T3aM7CN-eLn3yY-z08v5-XTx7evF_GQxVWWefmpYpxtoK9PhTDI0JaA2qEBxANnpipfQNLxmlS6KTgKXpmw7jZqZmjWaKb5Pvmx1V2M3oN7MEWQvVsEOMtwJL634N-PslVj6tciLLsuyqrPCpxeF4H-NGJMYbFTY5xWhH6Mo6oKxGUBdZPRwi6rgYwxoXvsA2wiCyNaJZ-sye_D3YK_kH68ycLwFbmyPd_9XEvPL71vJ30nhqjA</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Chen, Qiudong</creator><creator>Singer‐Englar, Tahli</creator><creator>Kobashigawa, Jon A.</creator><creator>Roach, Amy</creator><creator>Emerson, Dominic</creator><creator>Megna, Dominick</creator><creator>Ramzy, Danny</creator><creator>Catarino, Pedro</creator><creator>Patel, Jignesh K.</creator><creator>Kittleson, Michelle</creator><creator>Czer, Lawrence</creator><creator>Chikwe, Joanna</creator><creator>Esmailian, Fardad</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2475-4312</orcidid><orcidid>https://orcid.org/0000-0001-9308-3172</orcidid><orcidid>https://orcid.org/0000-0003-4492-2691</orcidid><orcidid>https://orcid.org/0000-0002-1445-6610</orcidid><orcidid>https://orcid.org/0000-0001-5728-0152</orcidid><orcidid>https://orcid.org/0000-0002-8169-0781</orcidid><orcidid>https://orcid.org/0000-0002-6154-1199</orcidid><orcidid>https://orcid.org/0000-0001-5744-2625</orcidid><orcidid>https://orcid.org/0000-0002-7328-5903</orcidid></search><sort><creationdate>202205</creationdate><title>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</title><author>Chen, Qiudong ; Singer‐Englar, Tahli ; Kobashigawa, Jon A. ; Roach, Amy ; Emerson, Dominic ; Megna, Dominick ; Ramzy, Danny ; Catarino, Pedro ; Patel, Jignesh K. ; Kittleson, Michelle ; Czer, Lawrence ; Chikwe, Joanna ; Esmailian, Fardad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Allografts</topic><topic>heart (allograft) function/dysfunction</topic><topic>heart disease</topic><topic>Heart Diseases</topic><topic>Heart Transplantation - adverse effects</topic><topic>Humans</topic><topic>organ perfusion and preservation</topic><topic>Organ Preservation</topic><topic>patient survival</topic><topic>Perfusion</topic><topic>Tissue Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Qiudong</creatorcontrib><creatorcontrib>Singer‐Englar, Tahli</creatorcontrib><creatorcontrib>Kobashigawa, Jon A.</creatorcontrib><creatorcontrib>Roach, Amy</creatorcontrib><creatorcontrib>Emerson, Dominic</creatorcontrib><creatorcontrib>Megna, Dominick</creatorcontrib><creatorcontrib>Ramzy, Danny</creatorcontrib><creatorcontrib>Catarino, Pedro</creatorcontrib><creatorcontrib>Patel, Jignesh K.</creatorcontrib><creatorcontrib>Kittleson, Michelle</creatorcontrib><creatorcontrib>Czer, Lawrence</creatorcontrib><creatorcontrib>Chikwe, Joanna</creatorcontrib><creatorcontrib>Esmailian, Fardad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Qiudong</au><au>Singer‐Englar, Tahli</au><au>Kobashigawa, Jon A.</au><au>Roach, Amy</au><au>Emerson, Dominic</au><au>Megna, Dominick</au><au>Ramzy, Danny</au><au>Catarino, Pedro</au><au>Patel, Jignesh K.</au><au>Kittleson, Michelle</au><au>Czer, Lawrence</au><au>Chikwe, Joanna</au><au>Esmailian, Fardad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2022-05</date><risdate>2022</risdate><volume>36</volume><issue>5</issue><spage>e14591</spage><epage>n/a</epage><pages>e14591-n/a</pages><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections. Results Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p &gt; .5). Conclusions In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.</abstract><cop>Denmark</cop><pmid>35030278</pmid><doi>10.1111/ctr.14591</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2475-4312</orcidid><orcidid>https://orcid.org/0000-0001-9308-3172</orcidid><orcidid>https://orcid.org/0000-0003-4492-2691</orcidid><orcidid>https://orcid.org/0000-0002-1445-6610</orcidid><orcidid>https://orcid.org/0000-0001-5728-0152</orcidid><orcidid>https://orcid.org/0000-0002-8169-0781</orcidid><orcidid>https://orcid.org/0000-0002-6154-1199</orcidid><orcidid>https://orcid.org/0000-0001-5744-2625</orcidid><orcidid>https://orcid.org/0000-0002-7328-5903</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0902-0063
ispartof Clinical transplantation, 2022-05, Vol.36 (5), p.e14591-n/a
issn 0902-0063
1399-0012
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11144456
source Wiley
subjects Allografts
heart (allograft) function/dysfunction
heart disease
Heart Diseases
Heart Transplantation - adverse effects
Humans
organ perfusion and preservation
Organ Preservation
patient survival
Perfusion
Tissue Donors
title Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T05%3A28%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%90term%20outcomes%20after%20heart%20transplantation%20using%20ex%20vivo%20allograft%20perfusion%20in%20standard%20risk%20donors:%20A%20single%E2%80%90center%20experience&rft.jtitle=Clinical%20transplantation&rft.au=Chen,%20Qiudong&rft.date=2022-05&rft.volume=36&rft.issue=5&rft.spage=e14591&rft.epage=n/a&rft.pages=e14591-n/a&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/ctr.14591&rft_dat=%3Cproquest_pubme%3E2620081162%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2620081162&rft_id=info:pmid/35030278&rfr_iscdi=true